

Andrew Gostine, MD, MBA

Chief Executive Officer

Agenda


- ☐ Artisight Platform
- ☐ AI Adoption Strategy
- ☐ AI Development Strategy
- ☐ Areas of Deployment
 - ☐ Procedural Locations
 - ☐ Patient Rooms
 - Clinics and Hospital Tracking



AI-Enabled Sensor Platform



Platform and Applications



Platform Installation

Operating Room of the Future



Patient Room of the Future





AI Development Strategy



Levels of Autonomous Driving

0

No Automation

Human control of all driving tasks

1

Driver Assistance

A single automated feature (cruise control)

2

Partial Automation

The vehicle can perform various functions, but requires human monitored tasks (+Lane Assist) 3

Conditional Automation

Addition of environmental detection.
Human override still required (+Collision Avoidance)

4

High Automation

Vehicle performs all driving tasks under specific circumstances. Human override available

5

Full Automation

The vehicle can perform all tasks under all conditions.

Human-monitored environment with increasingly automated work

Automated work with increasingly Almonitored environment



Levels of Autonomous Healthcare

Artisight •• 3 5 0 **Conditional** Full No Clinician Intelligent High **Automation Assistance Automation Automation Automation Assistance** Un-intelligent, All hospital-based The system can Sophisticated Automated The system can workflows entirely sensor-based perform semimonitoring with information perform all dependent on staff intelligent automated dissemination and intelligence-based monitoring monitoring (ex. information and mechanical (ex. camera in documentation computer vision dissemination and with some tasks (eg. robotic room) bed exit algorithm) documentation. mechanical work surgery).

Human intervention with increasingly automated monitoring or diagnosis

Automated monitoring or diagnosis with increasingly automated intervention

"Getting to [Level 5 Automation] is the goal for AVs, because the advantages of taking the driver completely out of the equation are clear and compelling. Not so in health care. In fact, quite the contrary, as the doctor-patient relationship is critical to outcomes.

Moreover, augmentation systems are far easier to develop and deploy and can be ready to use in years, not decades."

Justin Norden, MD, MBA, MPhil

NEJM, What AI in Health Care Can Learn from the Long Road to Autonomous Vehicles, March, 2022



Operating Room Applications



Level 1: Artisight Operating Room Monitoring™

• Artisight sets up video and audio streaming to enable nurses and physicians to monitor patients and surgical procedure progress in the operating rooms. This eliminates blind spots in workflows and provides an increase in operating room throughput. Small increases in throughput yield large ROI's.



Level 2: Artisight Intraoperative TeleConsultation™ and Artisight Translator Connect™

• Artisight sets up video and audio streaming to enable surgeons and anesthesiologist to talk to patients and staff from anywhere in the world. This reduces friction, enables new care models, increases contact between patients and clinicians, eliminates the need for bedside staff to perform clerical tasks, and improves patient outcomes.



Level 3: Artisight OR Coordination™

• Hospitals use Artisight's OR Coordination capabilities as an air traffic control system for the operating rooms. This software complements the remote monitoring of operating rooms to drive greater throughput and financial ROI.



Level 4: Artisight Ambient Co-pilot™

• Artisight's computer vision and voice recognition services start ambiently monitoring the operating room and patients to complete clinical documentation and coordinate throughput semi-autonomously. This allows hospitals to start scaling the above solutions across the entire health system.



Level 5: Artisight Full Ambient Artificial Intelligence™

• Artisight's co-pilot evolves to coordinate and monitor OR's fully autonomously. The AI handles patient monitoring, procedure length predictions, nursing and physician documentation, and charge capture for billing documentation and collections. This results in maximum OR efficiency.



Patient Room Applications



Level 1: Artisight Remote Patient Monitoring™

• Artisight sets up video and audio streaming to enable bedside nurses to monitor their patients. This eliminates blind spots in patient monitoring to prevent patient harm. Results from Artisight's deployment at Guthrie: https://www.healthcareitnews.com/news/guthrie-clinic-reduces-nurse-turnover-25-13-ai-platform



Level 2: Artisight TeleConsultation™ and Artisight Translator Connect™

Artisight sets up video and audio streaming to enable bedside physicians to talk to their patients from anywhere in the world.
 Reduces friction, increases contact between patients and clinicians, and improves patient outcomes. Results from Artisight's deployment at WellSpan: https://www.wellspan.org/news/story/wellspan-uses-ai-to-improve-patient-safety-address-nursing-burnout/N12897



Level 3: Artisight Remote Nursing Assistance™

• Hospitals use the Artisight platform and apps to enable bedside clinicians to work with remote clinicians. Remote clinicians make bedside clinicians 127% more clinical productive. This productivity gain reduces the number of clinical staff needed by 15.2%. Results from Artisight's integration with Epic Systems: https://www.epicshare.org/share-and-learn/guthrie-virtual-nursing



Level 4: Artisight Ambient Co-pilot™

• Artisight's computer vision and voice recognition services start monitoring patients and documenting clinical care for the bedside staff. This allows hospitals to scale this service across the entire health system. Results from Artisight's AI co-pilot at Avera Health: https://www.beckershospitalreview.com/digital-health/avera-health-plans-to-expand-virtual-nursing-to-37-hospitals.html



Level 5: Artisight Full Ambient Artificial Intelligence™

• Artisight's co-pilot evolves to fill the role of the remote nurse completely. The AI handles patient monitoring, patient predictions, nursing and physician documentation, and charge capture for billing documentation and collections. Results published in *Nature* by Artisight co-founder Eric Oermann, MD: https://www.nature.com/articles/s41586-023-06160-y





Explainable AI

<u></u>	Artisight
	A cloigine

Fall Prevention - Atrium Health		
Race Composition		
Non-Hispanic White	60%	
Hispanic	18%	
Black or African American	13%	
Asian	6%	
Other	3%	
Sex Composition		
Male/Female	53/47%	
Age Composition		
<18	4%	
18-35	12%	
35-55	18%	
55-65	29%	
>65	37%	
Time of Day Composition		
10p-5a	25%	
5a-10a	25%	
10a—5p	25%	
5p-10p	25%	



Privacy AEpid dEpid/dt Consulting, Inc. Statistical De-Identification Privacy Solutions Whiteboard Coordinator, Inc. Artisight, Inc. d/b/a 2370 Dorina Drive October 21, 2019 Northfield, IL 60093 Tim Koby PhD, MBA Chief Science Officer Whiteboard Coordinator, Inc. Andrew Gostine, MD, MBA As you know, Artisight, Inc. d/b/a Whiteboard Coordinator, Inc. (hereafter Whiteboard's and analyses of Whiteboard's conduct statistical disclosure review and analyses to conduct statistical disclosure review and analyses to conduct statistical disclosure review and analyses of whiteboard's engaged my services to conduct statistical disclosure review and analyses of whiteboard's engaged my services to conduct statistical disclosure review and analyses of whiteboard's engaged my services to conduct statistical disclosure review and analyses of whiteboard's engaged my services to conduct statistical disclosure review and analyses of whiteboard review and analyses of whiteboard review and analyses of whiteboard review and analyses of white As you know, Artisight, Inc. d/b/a Whiteboard Coordinator, Inc. (hereafter Whiteboard) has "Data") in order review and analyses of Whiteboard's "Data") in order review and analyses of "Data") in order analyses of whiteboard as a described in Appendix A, the "Data") in order review and analyses of "Data" in order review analyses of "Data" in order review and analyses of "Data" in order review and analyses of "Data" in order review and analyses of "Data" in order review analyses of "Data" in Chief Executive Officer Whiteboard Coordinator, Inc. engaged my services to conduct statistical disclosure review and analyses of Whiteboard's engaged my services to conduct statistical disclosure review and analyses of Whiteboard's in order the Appendix A, the "Data" under the Permanent Video Database (with data elements as described in Appendix A, the "House the Considered "statistically de-identified" under the Permanent Video Database (with data could be considered "statistically de-identified" under the Considered (statistically de-identified) and the Considered (stati Permanent Video Database (with data elements as described in Appendix Å, the "Data") in order the to: (1) determine whether this Data could be considered "statistically de-identified" under the to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated at Section 164.514 of the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered to the HIPAA privacy rule, promulgated to the HIPAA privacy rule 2370 Dorina Drive to: (1) determine whether this Data could be considered "statistically de-identified" under the Privacy of the HIPAA privacy rule, promulgated to: (1) determine whether this Data could be considered "statistically de-identified" under the Privacy of the HIPAA privacy of 1996 ("HIPAA Privacy and Accountability Act of 1996 ("HIPAA Privacy and Accountability Act of 1996 ("HIPAA Privacy of 1996) (Northfield, IL 60093 Expert Determination method: found at Section 164.514 of the HIPAA privacy rule, promulgated ("HIPAA privacy rule, promulgated privacy rule, p Dear Dr. Gostine and Dr. Koby: pursuant to the Health Insurance Portability and Accountability Act of 1996 ("HIPAA Privacy and Accountability Act of 1996 ("HIPAA Privacy and Conditions of assumptions which would be seen as a sumption of the Health Insurance Portability and Accountability Act of 1996 ("HIPAA Privacy Accountability Act of 1996 ("HIPAA Priva I. Overview and This letter includes a summary of the results of my statistical disclosure review and You analyses and my Expert Determination regarding the statistical de-identification of the Data. 1. <u>Overview.</u> This letter includes a summary of the results of my statistical disclosure review and You and You and This letter includes a summary of the results of my statistical de-identification of the Data. You are statistical de-identification of the Data with the statistical de-identification of the Data with a with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them. analyses and my Expert Determination regarding the statistical de-identification of the Data. You them with may share this letter with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them with any interested parties, including for purposes of providing them any interested parties, including for purposes of providing them any interested parties, including for purposes of providing them any interested parties, including for purposes of providing them any interested parties, including the parties of providing them any interested parties are provided to the providing them and the parties of may share this letter with any interested parties, including for purposes of providing them with information on Whiteboard's HIPAA decidentification activities described the statistical described on Whiteboard's HIPAA decidentification activities with the statistical described of my Expert Determination that the proposed Data complies with the statistical decidentification of my Expert Determination that the proposed Data complies with the statistical decidentification of my Expert Determination that the proposed Data complies with the statistical decidentification of my Expert Determination that the proposed Data complies with the statistical decidentification activities described herein of my Expert Determination that the proposed Data complies with the statistical decidentification activities described herein or informing them with the statistical decidentification activities described herein or informing them with the statistical decidentification activities described herein or my with the statistical decidentification activities described herein the statistical decidentification activities decidentification a information on Whiteboard's HIPAA de-identification activities described herein of informing activities described herein or informing activities described herein them of my Expert Determination that the proposed Data complies with the statistical deviation of my Expert Determination 164.514 of the HIPAA Privacy Rule. This letter will also the HIPAA Privacy Rule of the HIPAA Privacy Rule of the HIPAA Privacy Rule. This letter will also the HIPAA Privacy Rule of t identification provisions in Section 164.514 of the HIPAA Privacy Rule¹. This letter will also of the substantial knowledge of the serve as my verification to you that (i) I am an expert possessing substantial disclosure control, (ii) I serve as my verification to you that (i) I am an expert possessing substantial disclosure control, (ii) I serve as my verification to you that (i) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control, (iii) I am an expert possessing substantial disclosure control serve as my verification to you that (i) I am an expert possessing substantial knowledge of the control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial disclosure control, (ii) I am an expert possessing substantial knowledge of the control, (ii) I am an expert possessing substantial knowledge of the control of such statistical disclosure limitations, the control of such statistical disclosure limitations. theoretical, statistical and scientific principles and methods of statistical disclosure limitations, have considerable practical experience in the application of such statistical disclosure limitations. The term "Expert Determination" was first introduced by the Department of Health and Human Services Office of Civil Rights in their November 26, 2012 document "Guidance Regarding Methods for De-identification of Protected Health Information." The term "Expert Determination" was first introduced by the Department of Health and Human Services Office of Civil Rights in their November 26, 2012 document of Health Instruction of Protected Health Instruction of Protected The Instruction of Pro "statistical decidentification". Section 164.514 (b)(1)(i-ii) of the HPAA Privacy Rule specifies with generally accepted statistical and scientific principles and report person with appropriate knowledge of and experience with generally accepted statistical and scientific principles. Section 164.514 (b)(1)(i-ii) of the HIPAA Privacy Rule specifies that health information is not individually identifiable if "A specifies that health information is not individually identifiable if "A specifies that health information is not individually identifiable if "A specifies that health information is not individually identifiable; (i) Applying such principles and methods, determines that the risk is very specified in the properties of the principles and methods, determines that the risk is very specified in the properties of the principles and methods are principles are principles and methods are principles are principles and methods are principles and methods are principles and methods are principles and methods are principles are person with appropriate knowledge of and experience with generally accepted statistical methods, determines that the risk is very person with appropriate knowledge of and experience with generally accepted statistical methods, determines that the risk is very person with appropriate knowledge of and experience with generally accepted statistical and enholds, determines that the risk is very person with appropriate knowledge of and experience with generally accepted statistical and enholds, determines that the risk is very person with appropriate knowledge of and experience with person with other reasonably available information, by an anticipated of the reasonably available information could be used, alone or in combination with other reasonably available information could be used, alone or in combination with other reasonably available information could be used, alone or in combination with other reasonable and the risk is very person with appropriate knowledge of and experience with person with other reasonable and methods, determines that the risk is very person with appropriate knowledge of and experience with person with appropriate knowledge of and experience with person with appropriate and methods, and the risk is very person with appropriate knowledge of and experience with person with appropriate knowledge of an experience with appropriate knowledge of a person with a person with a For rendering information could be used, alone or in combination; and (ii) Documents the methods and results of the analysis small that the information could be used, alone or in combination; and (ii) Documents the methods and results of the analysis and the information could be used, alone or in combination; and (ii) Documents the methods and results of the information to identify an individual who is a subject of the information; and (ii) Documents the methods and results of the information to identify an individual who is a subject of the information; and (ii) Documents the methods and results of the information to identify an individual who is a subject of the information; and (iii) Documents the methods and results of the information to identify an individual who is a subject of the information. we recover a minimum of the many and the model of the information; and (ii) Documents the methods and results of the analysis small that the information could be used, alone or in combination; and (ii) Documents the methods and results of the analysis treipient to identify an individual who is a subject of the information; and (ii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information; and (iii) Documents the methods and results of the information to the informa

recipient to identify an individua, that justify such determination;

October 21, 2019

environment of "reasonably available" data which could be used in data intrusion attempts. analyses environment of "reasonably available" data which could be used in data intrusion attempts.

supporting these findings will still hold in the future and have not been altered by important Finally, so as to confirm that the conclusions of these de-identification determination analyses changes in demographic characteristics that constitute the quasi-identifier variable sets, it is supporting these findings will still hold in the future and have not been altered by important recommended that re-analysis for statistical disclosure risks be performed every three vears, so changes in demographic characteristics that constitute the quasi-identifier variable sets, it is long as the Data is still being used.

Sets, it is years, so

IV. Conclusion. So long as (a) the Data to be used is limited to only those data elements set forth in Part III hereof remain IV. <u>Conclusion</u>. So long as (a) the Data to be used is limited to only those data elements set forth satisfied, it is my professional finding that the risk is very small that the Data to be used, alone or in Appendix A; and (b) the general conditions and assumptions set forth in Part III hereof remain in connection with other reasonably available information by the anticipated recipients, to satisfied, it is my professional finding that the risk is very small that the Data to be used, alone or identify an individual who is a subject of such data and accordingly it is my opinion that the Data to be used, alone or in connection with other reasonably available information by the anticipated recipients, to meets the requirements for Expert Determination of statistical desidentification as set forth in identify an individual who is a subject of such data, and accordingly it is my opinion that the Data Section 164.514 of the HIPAA Privacy Rule, thereby satisfying the conditions set forth in meets the requirements for Expert Determination of statistical de-identification as set forth in Sections 164.514 of the HIPAA Privacy Rule, thereby satisfying the conditions set forth in Sections 164.514 (a)-(b)(1) of the HIPAA Privacy Rule, Increby

This Expert Determination remains effective until October 21, 2025, unless there are any definition of This Expert Determination remains effective until October 21, 2025, unless there are any Determination of statistical de-identification, changes in the availability of technologies that Substantive changes in the external data environment, changes in regulatory definition of statistical de-identification, changes in the availability of technologies that the conduct of re-identification attacks, changes in the data elements Determination of statistical de-identification, changes in the availability of technologies that contained in this Data stream. or changes to the de-identification volicies, procedures and

importantly facilitate the conduct of re-identification attacks, changes in the data elements on this Data stream, or changes to the de-identification policies, procedures and control re-identification risks for this Data in which case a contained in this Data stream, or changes to the de-identification policies, procedures and new evaluation of statistical de-identification risks for this Data in which case a control review of these practices that are used to manage and control re-identification risks for this Data in which case a consideration will be a part of this ongoing Expert Determination de-identification process. new evaluation of statistical de-identification will be required. Continued annual reviews of the a part of this ongoing E_{X} pert D etermination de-identification P process.


Daniel C. Barth-Jones, M.P.H., Ph.D. President, dEpid/dt Consulting, Inc.

Assistant Professor of Clinical Epidemiology $D_{epartment}$ of $E_{pidemiology}$ Mailman School of Public Health

Columbia University

The Only KLAS Ranked Smart Hospital Vendor








Patient Room








Epic MyChart Bedside Hosted by Artisight






Epic Native Applications






TeleMonitoring





TeleConsult





Translation Services

